Squarepoint Ops LLC Increases Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Squarepoint Ops LLC lifted its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 22.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 178,892 shares of the company's stock after buying an additional 33,088 shares during the period. Squarepoint Ops LLC owned about 0.21% of IDEAYA Biosciences worth $4,598,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Barclays PLC raised its holdings in shares of IDEAYA Biosciences by 188.8% during the 3rd quarter. Barclays PLC now owns 181,170 shares of the company's stock valued at $5,739,000 after buying an additional 118,438 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of IDEAYA Biosciences by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock valued at $51,121,000 after buying an additional 43,226 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of IDEAYA Biosciences by 444.2% during the 4th quarter. SG Americas Securities LLC now owns 18,486 shares of the company's stock valued at $475,000 after buying an additional 15,089 shares in the last quarter. WCM Investment Management LLC purchased a new position in shares of IDEAYA Biosciences during the 4th quarter valued at about $6,030,000. Finally, abrdn plc raised its holdings in shares of IDEAYA Biosciences by 31.7% during the 4th quarter. abrdn plc now owns 306,723 shares of the company's stock valued at $7,883,000 after buying an additional 73,893 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on IDYA shares. Stephens restated an "overweight" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a research report on Friday, February 14th. JPMorgan Chase & Co. raised their price target on IDEAYA Biosciences from $63.00 to $66.00 and gave the stock an "overweight" rating in a research report on Thursday, May 22nd. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $54.27.

IDEAYA Biosciences Stock Performance

Shares of IDYA traded up $0.23 on Friday, reaching $20.28. The stock had a trading volume of 900,123 shares, compared to its average volume of 1,007,986. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -6.15 and a beta of 0.26. The company has a 50-day simple moving average of $17.74 and a 200-day simple moving average of $21.60. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter in the prior year, the firm posted ($0.53) earnings per share. On average, analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.